Nautilus Biotechnology Reports Q4 Earnings and 2026 Outlook

Written by Emily J. Thompson, Senior Investment Analyst

Source: seekingalpha

Updated: 6 days ago

0mins

NAUT+8.71%

Should l Buy NAUT?

Source: seekingalpha

Earnings Performance: Nautilus Biotechnology reported a Q4 GAAP EPS of -$0.11, beating expectations by $0.03, indicating initial success in cost control despite remaining in the red.
Cash Position: As of December 31, 2025, the company had $156.1 million in cash, cash equivalents, and investments, reflecting a degree of financial stability that can support future operational needs in the current economic climate.
2026 Outlook: The company anticipates no material revenue from its Early Access Program engagements in 2026, while expecting operating expenses to rise by 15-20% year-over-year, which may pressure profitability.
Sufficient Funding: Based on its cash reserves as of December 31, 2025, Nautilus Biotechnology believes it has adequate resources to fund operations through 2027, demonstrating confidence and foresight in its financial management.

Trade with 70% Backtested Accuracy

Stop guessing "Should I Buy NAUT?" and start using high-conviction signals backed by rigorous historical data.

Analyst Views on NAUT

Wall Street analysts forecast NAUT stock price to rise

2 Analyst Rating

2 Buy

0 Hold

0 Sell

Moderate Buy

Current: 2.410

Low

2.50

Averages

2.50

High

2.50

Current: 2.410

Low

2.50

Averages

2.50

High

2.50

Guggenheim

Buy

maintain

2026-02-27

New

Reason

Guggenheim

Price Target

AI Analysis

2026-02-27

New

maintain

Buy

Reason

Guggenheim raised the firm's price target on Nautilus Biotechnology to $4 from $2.50 and keeps a Buy rating on the shares. Every aspect of the Q4 report firms up Nautilus' foundation, showing line of sight to revenue, "albeit modest," this year and in 2027, the analyst tells investors in a post-earnings note.

About NAUT

Nautilus Biotechnology, Inc. is a development stage life sciences company. The Company is engaged in creating platform technology for quantifying and unlocking the complexity of the human proteome. The Company is focused on transforming the field of proteomics by democratizing access to the proteome and enabling fundamental advancements across human health and medicine. The Company's platform end-to-end solution comprised of the proteome analysis system, consumables, and software. The Company’s products include Proteome Analysis System, and Reagent Kits. Its proteome analysis system is a high-resolution optical imaging system coupled with integrated fluidics and liquid handling sub-systems. The Company’s Reagent Kits are comprised of four main components: sample preparation, flow cell(s), multi-affinity probe reagents, and instrument buffers used to perform multi-cycle analysis runs.

About the author

Emily J. Thompson

Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.

Nautilus Biotechnology Q4 2025 Earnings Call Highlights

6 days agoseekingalpha

Successful Product Launch: Nautilus unveiled the Voyager instrument at the US Human Proteome Organization Conference, receiving positive feedback that indicates strong interest from researchers in new protein measurement technologies, suggesting a growing market demand.
Early Access Program Initiation: The company launched the Early Access Program for Iterative Mapping ahead of schedule, marking a transition from development to active customer engagement, which is expected to enhance customer relationships and drive future revenue growth.
Improved Financial Performance: Total operating expenses for Q4 2025 were $15.4 million, a 23% decrease year-over-year, with cash burn at $50.2 million, down from 2024, demonstrating effective cost control and resource allocation.
Optimistic Future Outlook: The company anticipates a 15%-20% increase in total operating expenses for 2026, with plans for primary revenue growth to begin in 2027, reflecting Nautilus's confidence in its commercialization strategy and market positioning.